Dr Reddy's Laboratories has warned that any increase in US tariffs on generic medicines is likely to make drugs more expensive. The company's leadership indicated that higher import costs would eventually be reflected in medicine prices, adding pressure to a market where affordability is a major concern.
According to CEO Erez Israeli, moving manufacturing operations to the United States is not a realistic solution. His remarks suggest that relocating large-scale generic drug production would be difficult from both an operational and economic standpoint, especially for companies that already rely on established global supply networks.
The company is not planning any immediate special measures in response to the tariff discussion. Instead, Dr Reddy's appears to be taking a wait-and-watch approach as it monitors how US trade policy develops and what it could mean for the generics business.
The comments highlight a broader concern for pharmaceutical exporters: trade barriers can disrupt cost-efficient supply chains and raise prices for end buyers. For generic drugmakers, the issue is especially significant because the business depends on producing medicines at scale while keeping prices competitive.
